|
|
Taiwan Academic Institutional Repository >
Browse by Author
|
"blanc j f"
Showing items 11-15 of 15 (2 Page(s) Totally)
<< < 1 2
View [10|25|50] records per page
| 國立成功大學 |
2018 |
Phase II studies with refametinib or refametinib plus sorafenib in patients with RAS-mutated hepatocellular Carcinoma
|
Lim, H.Y.;Merle, P.;Weiss, K.H.;Yau, T.;Ross, P.;Mazzaferro, V.;Blanc, J.-F.;Ma, Y.T.;Yen, C.J.;Kocsis, J.;Choo, S.P.;Sukeepaisarnjaroen, W.;Gerolami, R.;Dufour, J.-F.;Gane, E.J.;Ryoo, B.-Y.;Peck-Radosavljevic, M.;Dao, T.;Yeo, W.;Lamlertthon, W.;Thongsawat, S.;Teufel, M.;Roth, K.;Reis, D.;Childs, B.H.;Krissel, H.;Llovet, J.M. |
| 國立成功大學 |
2018 |
Survival with nal-IRI (liposomal irinotecan) plus 5-fluorouracil and leucovorin versus 5-fluorouracil and leucovorin in per-protocol and non-per-protocol populations of NAPOLI-1: Expanded analysis of a global phase 3 trial
|
Chen, L.-T.;Siveke, J.T.;Wang-Gillam, A.;Li, C.-P.;Bodoky, G.;Dean, A.P.;Shan, Y.-S.;Jameson, G.S.;Macarulla, T.;Lee, K.-H.;Cunningham, D.;Blanc, J.-F.;Chiu, Chiu C.-F.;Schwartsmann, G.;Braiteh, F.S.;Mamlouk, K.;Belanger, Belanger B.;de, Jong F.A.;Hubner, R.A. |
| 國立成功大學 |
2018 |
Alpha-fetoprotein kinetics in patients with hepatocellular carcinoma receiving ramucirumab or placebo: An analysis of the phase 3 REACH study
|
Chau, I.;Park, J.O.;Ryoo, B.-Y.;Yen, C.-J.;Poon, R.;Pastorelli, D.;Blanc, J.-F.;Kudo, M.;Pfiffer, T.;Hatano, E.;Chung, H.C.;Kopeckova, Kopeckova K.;Phelip, J.-M.;Brandi, G.;Ohkawa, S.;Li, C.-P.;Okusaka, T.;Hsu, Y.;Abada, P.B.;Zhu, A.X. |
| 國立成功大學 |
2016 |
Expanded analyses of NAPOLI-1: Phase 3 study of nal-IRI (MM-398), with or without 5-fluorouracil (5FU) and leucovorin (LV), versus 5-fluorouracil and leucovorin (5FU/LV), in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy
|
Siveke, Jens T.;Chen, Li-Tzong;Von Hoff, Daniel D;Li, Chung-Pin;Wang-Gillam, Andrew;Bodoky, Gyorgy;Dean, Andrew;Shan, Yan-Shen;Jameson, Gayel S;Macarulla, T.;Lee, K-H;Cunningham, D.;Blanc, J-F;Hubner, R. A.;Chiu, C-F;Schwartsmann, G.;Braiteh, F.;Moyo, V.;Belanger, B.;Bayever, E. |
| 國立成功大學 |
2015-09 |
Ramucirumab (RAM) as a second-line treatment in patients with advanced hepatocellular carcinoma (HCC) following first-line therapy with sorafenib in the randomized phase III REACH study: Analysis of alpha-fetoprotein (AFP) kinetics during treatment
|
Chau, I.; Park, J. O.; Ryoo, B. Y.; Yen, C. J.; Poon, R.; Pastorelli, D.; Blanc, J. F.; Kudo, M.; Pfiffer, T. F.; Hatano, E.; Chung, H. C.; Kubackova, K.; Phelip, J. M.; Brandi, G.; Ohkawa, S.; Li, C. P.; Okusaka, T.; Yang, L.; Abada, P.; Zhu, A. |
Showing items 11-15 of 15 (2 Page(s) Totally)
<< < 1 2
View [10|25|50] records per page
|
